Sep 2026· Cancer Science· 0 citations· 46 references
Medicine
TL;DR
The 12‐gene immune‐related gene signature (IRGS) is defined as a complementary immune‐associated molecular biomarker for prognostic stratification in MM and provide a framework linking prognosis with multicellular transcriptional context, somatic mutational characteristics, and candidate therapeutic vulnerabilities.
Abstract
ABSTRACT The immune microenvironment contributes substantially to the biological and clinical heterogeneity of multiple myeloma (MM), yet immune‐related molecular biomarkers with reproducible prognostic value remain limited. Here, we developed a 12‐gene immune‐related gene signature (IRGS) using an integrative machine‐learning framework and evaluated its prognostic performance across multiple MM cohorts. The IRGS consistently stratified overall survival and remained independently associated with outcome after adjustment for established clinical covariates. Its prognostic discrimination was comparable to that of IFM15 and generally exceeded that of MRCIX6 and a mitophagy‐related signature across the evaluated validation datasets. Single‐cell RNA sequencing further revealed marked cell type‐dependent variation in the activity of the 12‐gene module, with comparatively low activity in plasma cells and higher activity in several non‐plasma compartments, indicating that the bulk‐derived IRGS reflects a multicellular bone marrow transcriptional context rather than an exclusively malignant plasma cell intrinsic program. Somatic mutation analysis identified distinct mutational patterns between IRGS‐defined groups, including relative enrichment of DIS3 mutations in the low‐IRGS group and MUC16 mutations in the high‐IRGS group, together with a modestly higher tumor mutational burden in low‐IRGS patients. Transcriptome‐based drug‐response prediction further suggested differential therapeutic vulnerabilities, with high‐ and low‐IRGS groups showing distinct predicted sensitivity patterns across apoptosis‐, DNA damage‐, BET‐, checkpoint‐, and replication‐stress‐related agents. Collectively, these findings define the IRGS as a complementary immune‐associated molecular biomarker for prognostic stratification in MM and provide a framework linking prognosis with multicellular transcriptional context, somatic mutational characteristics, and candidate therapeutic vulnerabilities.
Novel molecular markers and immune regulatory pathways are uncovered, providing insight into MM prognosis and possible therapeutic strategies, using integrated bioinformatics, machine learning, and experimental approaches.
Wen-Jing Li, Li Li, Yu Sun et al.· American journal of translat...· 0 citations
Cellular senescence exerts context‐dependent effects on breast cancer progression and therapeutic response through dynamic interactions with the tumor microenvironment; however, its pathological manifestations, cellular organization, and clinical significance remain incompletely understood. In this study, we integrated...
Song-Yun Zhao, Zi-Jian Lin, Yan-Ming Chen et al.· The FASEB Journal· 0 citations
Background Chemotherapy is the mainstay of systemic treatment for colorectal cancer (CRC), but drug resistance and tumor heterogeneity markedly limit survival. Mitochondrial metabolism is increasingly recognized as a regulator of tumor progression, immune contexture, and therapeutic response. However, the prognostic re...
Jin-Fen Tang, Deng-Gao Yuan, Zhou Wu et al.· Human Mutation· 0 citations
It is demonstrated that immune-related hallmark pathway activity contributes substantially to glioblastoma biological heterogeneity and patient prognosis, and the proposed pathway-based prognostic framework provides a biologically interpretable approach for survival stratification.
Ahmed M. Abdelmaguid, Rasha M. A. Eltanany, Manal F. El-khadragy et al.· Discover Oncology· 0 citations
These findings identify eight MP-related hub genes as candidate prognostic biomarkers and provide a risk model with acceptable predictive performance, offering insights into the immune-metabolic interplay in MM and suggesting potential avenues for personalized therapeutic strategies.
Ran Wang, Jing-Wei Zhang, Jing Qi et al.· Journal of Visualized Experi...· 0 citations
Nodal T-follicular helper cell lymphoma (nTFHL), most commonly of angioimmunoblastic type, exhibits heterogeneous clinical outcomes that are not fully explained by current clinical and biological variables. While genetic alterations have been extensively investigated, its proteomic landscape remains largely unexplored....
D. Beauvais, Y. Zirem, T. Cardon et al.· American journal of hematolo...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.